In this video, David Williamson reviews some of his favorite biotech firms. Many analysts have thrown their weight behind Biogen (BIIB +0.60%) and its new BG12 drug for multiple sclerosis. However, David favors Gilead (GILD 0.13%) over Biogen since Gilead has a larger, more diverse product pipeline. Celgene (CELG +0.00%) is the No. 1 biotech in David's opinion since it also has blockbuster drugs but a PEG of less than 1.0. Amgen (AMGN 0.44%) is a big company with more products in development than most people realize. Overall, for value and future earnings potential, David likes Celgene the best.
